止血瓣膜市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年，全球止血瓣膜市場規模達1.802億美元，預計年複合成長率將達5.4%，到2034年將達到3.046億美元。這主要得益於微創手術中對導絲和導管使用便利性的需求日益成長，同時也能有效控制失血。隨著醫療保健產業持續轉向微創治療方案，止血瓣膜等血液管理工具的重要性日益凸顯。受人口老化、久坐不動的生活方式和不良飲食習慣的影響，全球心血管疾病發病率穩步上升，這顯著增加了對導管介入治療的需求。

血管成形術、支架置入術和瓣膜置換術等手術的實施率日益成長，對可靠、高性能止血瓣膜的需求也日益成長，這些瓣膜能夠保持入路密封，同時確保器械平穩移動。外科醫生和介入科醫生越來越青睞那些能夠簡化複雜手術並改善患者預後的技術，這推動著瓣膜設計、耐用性和易操作性的穩定創新。此外，醫療保健投資的增加、全球老年人口的不斷成長以及微創手術的日益普及，都將在未來十年維持市場的成長動能。

心臟病學和神經病學領域對微創手術的日益青睞，進一步推動了止血瓣膜的廣泛應用。這些手術現已被視為標準治療方法，具有減少病患創傷、縮短住院時間和降低術後風險等優勢。隨著介入手術日益複雜，臨床醫生優先考慮新一代止血瓣膜，其密封性能更強，可單手操作，並與各種導管尺寸和器械廣泛相容。

按產品類型分類，止血閥Y型連接器在2024年佔據市場主導地位，創造了7,200萬美元的收入。其廣泛應用源自於其在複雜干預中的適應性，尤其是在需要同時使用多種器械的干涉中。 Y型連接器使醫生能夠有效地管理血流，並最大限度地減少血管通路操作過程中的失血。持續的設計改進，包括更好的密封性和更高的設備耐用性，使這些連接器在微創環境中執行高精度任務時更加可靠。

從應用角度來看，血管攝影領域在2024年佔據了最大的市場佔有率，達到64.2%，價值1.157億美元。止血瓣在血管攝影手術中至關重要，用於控制血流並在插入和拔出導管時保持安全密封。止血瓣的使用可以減少失血和手術併發症，使其成為造影劑注射和血管成像過程中不可或缺的工具。先進成像技術的興起進一步推動了對可靠性和易操作的高性能瓣膜的需求。

北美引領全球止血瓣膜市場，2024年市場規模達7,360萬美元，得益於心臟病學和神經病學領域微創手術的激增。慢性病住院率的上升持續推動導管介入治療的應用，直接影響對先進止血瓣膜技術的需求。美國憑藉其強大的醫療基礎設施、政府對醫療創新的支持以及行業領先企業的集中佈局，繼續保持市場領先地位。

塑造全球止血瓣膜市場格局的關鍵參與者包括深圳安特醫療、雅培實驗室、樂普醫療科技、波士頓科學、維貢、尼普洛醫療、貝朗梅爾松根、德羅伊爾工業、SCW Medicath、科德寶醫療、Argon Medical Devices、泰爾茂、泰利福、美瑞特醫療系統和北京迪瑪克醫療科技。各公司正致力於提高產品耐用性、降低插入阻力並改善單手操作設計。領先企業持續擴展產品組合，提供耐壓瓣膜選項和更高的導管相容性，同時與醫院、診斷中心和全球經銷商建立策略聯盟，以擴大市場覆蓋範圍並促進長期成長。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 心血管疾病盛行率不斷上升
    • 微創手術的需求不斷成長
    • 止血閥的技術進步
  • 產業陷阱與挑戰
    • 缺乏熟練的專業人員
    • 嚴格的監管情景
• 成長潛力分析
• 監管格局
• 川普政府關稅
  • 對貿易的影響
    • 貿易量中斷
    • 報復措施
  • 對產業的影響
    • 供應方影響（原料）
      • 主要材料價格波動
      • 供應鏈重組
      • 生產成本影響
    • 需求面影響（售價）
      • 價格傳導至終端市場
      • 市佔率動態
      • 消費者反應模式
  • 受影響的主要公司
  • 策略產業反應
    • 供應鏈重組
    • 定價和產品策略
    • 政策參與
  • 展望與未來考慮
• 技術格局
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：依產品類型，2021 - 2034 年

• 主要趨勢
• 止血閥Y型連接器
• 雙Y型接頭止血閥
• 單手止血閥
• 其他產品類型

第6章：市場估計與預測：按應用，2021 - 2034 年

• 主要趨勢
• 血管攝影
• 血管成形術

第7章：市場估計與預測：依最終用途，2021 - 2034 年

• 主要趨勢
• 醫院
• 門診手術中心（ASC）
• 其他最終用途

第8章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國

第9章：公司簡介

• Argon Medical Devices
• Abbott Laboratories
• B. Braun Melsungen
• Beijing Demax Medical Technology
• Boston Scientific
• DeRoyal Industries
• Freudenberg Medical
• Lepu Medical Technology
• Merit Medical Systems
• Nipro Medical
• SCW Medicath
• Shenzhen Antmed
• Teleflex
• Terumo
• Vygon

The Global Hemostasis Valve Market was valued at USD 180.2 million in 2024 and is estimated to grow at a CAGR of 5.4% to reach USD 304.6 million by 2034, driven by the rising need to facilitate the use of guidewires and catheters during minimally invasive surgeries while controlling blood loss. As the healthcare sector continues to shift toward less invasive treatment options, the importance of blood management tools like hemostasis valves is becoming more prominent. The steady increase in cardiovascular diseases worldwide, fueled by aging populations, sedentary lifestyles, and poor dietary habits, has significantly boosted the demand for catheter-based interventions.

Procedures such as angioplasties, stent placements, and valve replacements are performed at a growing rate, creating a heightened need for reliable, high-performance hemostasis valves that can maintain a sealed access point while allowing smooth device movement. Surgeons and interventionalists increasingly favor technologies that simplify complex procedures and enhance patient outcomes, driving steady innovation in valve design, durability, and ease of operation. Additionally, rising healthcare investments, the expanding global geriatric population, and the growing acceptance of minimally invasive surgeries are poised to sustain the market's upward trajectory over the next decade.

The increasing preference for minimally invasive procedures across cardiology and neurology further supports the widespread adoption of hemostasis valves. These procedures are now considered the standard of care, offering benefits like reduced patient trauma, shorter hospital stays, and lower postoperative risks. As interventional procedures become more complex, clinicians are prioritizing next-generation hemostasis valves featuring enhanced sealing capabilities, one-handed operation, and broad compatibility with various catheter sizes and devices.

By product type, hemostasis valve Y-connectors dominated the market in 2024, generating USD 72 million in revenue. Their widespread use comes from their adaptability during complex interventions, especially those that require the concurrent use of multiple instruments. Y-connectors allow practitioners to manage blood flow effectively and minimize blood loss during vascular access procedures. Continuous improvements in design, including better sealing and increased device durability, have made these connectors more reliable for high-precision tasks in minimally invasive environments.

Based on application, the angiography segment captured the largest market share of 64.2% in 2024, accounting for USD 115.7 million. Hemostasis valves are essential during angiographic procedures for controlling blood flow and maintaining a secure seal when inserting and withdrawing catheters. Their use reduces blood loss and procedural complications, making them indispensable tools during contrast injections and vessel imaging. The rise of advanced imaging technologies further boosts demand for high-performance valves that offer reliability and ease of handling.

North America led the global hemostasis valve market, reaching USD 73.6 million in 2024, fueled by the surge in minimally invasive procedures in cardiology and neurology. Increasing rates of hospitalization due to chronic diseases continue to drive the adoption of catheter-based interventions, directly impacting the demand for advanced hemostasis valve technologies. The U.S. maintains leadership, backed by a strong healthcare infrastructure, government support for medical innovation, and a concentrated presence of leading industry players.

Key players shaping the Global Hemostasis Valve Market landscape include Shenzhen Antmed, Abbott Laboratories, Lepu Medical Technology, Boston Scientific, Vygon, Nipro Medical, B. Braun Melsungen, DeRoyal Industries, SCW Medicath, Freudenberg Medical, Argon Medical Devices, Terumo, Teleflex, Merit Medical Systems, and Beijing Demax Medical Technology. Companies are focusing on advancing product durability, lowering insertion resistance, and enhancing one-handed operational designs. Leaders continue to expand portfolios with pressure-resistant valve options and greater catheter compatibility while building strategic alliances with hospitals, diagnostic centers, and global distributors to strengthen market reach and foster long-term growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cardiovascular diseases
    • 3.2.1.2 Growing demand for minimally invasive surgeries
    • 3.2.1.3 Technological advancement in hemostasis valve
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of skilled professionals
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Technological landscape
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Hemostasis valve Y-connectors
• 5.3 Double Y-connector hemostasis valves
• 5.4 One-handed hemostasis valves
• 5.5 Other product types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Angiography
• 6.3 Angioplasty

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers (ASCs)
• 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Argon Medical Devices
• 9.2 Abbott Laboratories
• 9.3 B. Braun Melsungen
• 9.4 Beijing Demax Medical Technology
• 9.5 Boston Scientific
• 9.6 DeRoyal Industries
• 9.7 Freudenberg Medical
• 9.8 Lepu Medical Technology
• 9.9 Merit Medical Systems
• 9.10 Nipro Medical
• 9.11 SCW Medicath
• 9.12 Shenzhen Antmed
• 9.13 Teleflex
• 9.14 Terumo
• 9.15 Vygon